Literature DB >> 19635225

Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer.

Jill A Foster1, Maziar Abdolrasulnia, Hamidreza Doroodchi, Joan McClure, Linda Casebeer.   

Abstract

BACKGROUND: Studies of adherence to breast cancer guidelines have often focused on primary therapies, but concordance with other guideline recommendations has not been examined as extensively. This study assesses the knowledge and practice patterns of medical oncologists in the United States to inform education and quality improvement initiatives that can improve breast cancer care.
METHODS: A survey containing case vignettes and related questions was developed to examine oncologists' clinical decision-making in evaluating and treating women with early breast cancer. The instrument was distributed to a random sample of 742 oncologists in the United States and yielded 205 responses (27.6% response rate). Responses from 184 practicing medical oncologists were analyzed relative to the 2007 NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.
RESULTS: Most oncologists made guideline-consistent choices in clarifying indeterminate human epidermal growth factor 2 (HER2) status (85%), initial treatment for early breast cancer (95%), and postsurgical management of locally advanced breast cancer (82%). Guideline-discordant choices were seen in the lack of clip placement before neoadjuvant chemotherapy (36%), unnecessary use of PET scanning for initial assessment (34%), inappropriate assessment of menopausal status (33%), inappropriate use of tumor markers (22%), and use of chest imaging (16%) during posttherapeutic surveillance.
CONCLUSIONS: Oncologists often make guideline-consistent choices, but discordant clinical decisions may occur in important aspects of care for early breast cancer. Broadening the diffusion and adoption of guideline recommendations is an important mechanism for addressing these gaps and may substantially improve the quality of breast cancer care.

Entities:  

Mesh:

Year:  2009        PMID: 19635225     DOI: 10.6004/jnccn.2009.0049

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  16 in total

Review 1.  In vivo imaging in cancer.

Authors:  John Condeelis; Ralph Weissleder
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-09-22       Impact factor: 10.005

2.  Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.

Authors:  Arif H Kamal; Charles L Loprinzi; Carol Reynolds; Amylou C Dueck; Xochiquetzal J Geiger; James N Ingle; Robert W Carlson; Timothy J Hobday; Eric P Winer; Matthew P Goetz
Journal:  Oncologist       Date:  2011-09-20

Review 3.  Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.

Authors:  Robin K Kelley; Stephanie L Van Bebber; Kathryn A Phillips; Alan P Venook
Journal:  J Natl Compr Canc Netw       Date:  2011-01       Impact factor: 11.908

4.  Tumor marker usage and medical care costs among older early-stage breast cancer survivors.

Authors:  Scott D Ramsey; N Lynn Henry; Julie R Gralow; Dana K Mirick; William Barlow; Ruth Etzioni; David Mummy; Rahber Thariani; David L Veenstra
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

Review 5.  Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America.

Authors:  Tracy Spinks; Heidi W Albright; Thomas W Feeley; Ron Walters; Thomas W Burke; Thomas Aloia; Eduardo Bruera; Aman Buzdar; Lewis Foxhall; David Hui; Barbara Summers; Alma Rodriguez; Raymond Dubois; Kenneth I Shine
Journal:  Cancer       Date:  2011-11-01       Impact factor: 6.860

6.  Examining the introduction of a supportive care screening and referral process for cancer patients: how does practice compare with protocols?

Authors:  Melanie Regan; Eli Ristevski; Rebecca Jones; Sibilah Breen; Allison Hartney
Journal:  Support Care Cancer       Date:  2011-01-06       Impact factor: 3.603

7.  Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis.

Authors:  Rahber Thariani; Norah Lynn Henry; Scott D Ramsey; David K Blough; Bill Barlow; Julie R Gralow; David L Veenstra
Journal:  J Comp Eff Res       Date:  2013-05       Impact factor: 1.744

Review 8.  Promoting quality and evidence-based care in early-stage breast cancer follow-up.

Authors:  N Lynn Henry; Lynn N Henry; Daniel F Hayes; Scott D Ramsey; Gabriel N Hortobagyi; William E Barlow; Julie R Gralow
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

9.  Patterns of Surveillance Advanced Imaging and Serum Tumor Biomarker Testing Following Launch of the Choosing Wisely Initiative.

Authors:  Randy C Miles; Christoph I Lee; Qin Sun; Aasthaa Bansal; Gary H Lyman; Jennifer M Specht; Catherine R Fedorenko; Mikael Anne Greenwood-Hickman; Scott D Ramsey; Janie M Lee
Journal:  J Natl Compr Canc Netw       Date:  2019-07-01       Impact factor: 12.693

10.  Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?

Authors:  Steven J Katz; Sarah T Hawley; Irina Bondarenko; Reshma Jagsi; Kevin C Ward; Timothy P Hofer; Allison W Kurian
Journal:  Breast Cancer Res Treat       Date:  2017-07-08       Impact factor: 4.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.